CASP4 Can Be a Diagnostic Biomarker and Correlated with Immune Infiltrates in Gliomas

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Jan 30

PMID 36713560

Authors

Guopeng Tian

Qiao Li

Liang Niu

Yusong Luo

Hongyu Wang

Wei Kang

Xiang Fang

Shengwei Bai

Guoqiang Yuan

Yawen Pan

Affiliations

Soon will be listed here.

Abstract

Background: Gliomas are the most common and invasive malignant tumors that originate in the central nervous system. Currently, the primary treatment modality for gliomas is maximum surgical resection, supplemented by radiotherapy and chemotherapy. However, the long-term survival rate has not signifificantly increased. Pyroptosis is a new form of programmed lytic death that has been recently discovered. Caspase 4 (CASP4) plays a key role in pyroptosis. Many studies have shown that pyroptosis is not only related to inflflammation but is also closely related to the occurrence and development of most tumors. This study aimed to prove that CASP4 has a key role in the mechanism of gliomas.

Methods: We used expression data from The Cancer Genome Atlas and the Chinese Glioma Genome Atlas to explore the relationship between CASP4 expression and glioma prognosis. The differential expression of CASP4 in gliomas and normal tissues was fifirst tested, and then the connection between CASP4 and tumor prognosis was explored. The relationship between CASP4 expression and immune cell infifiltration was also investigated. Finally, the possible pathways were analyzed using Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and Gene Set Enrichment Analysis.

Results: CASP4 was highly expressed and associated with a signifificantly lower survival rate in patients with glioma. It could also inflfluence immune cell infifiltration by releasing cytokines.

Conclusion: CASP4 can be a diagnostic biomarker and is a promising therapeutic target for gliomas.

Citing Articles

Forms of Non-Apoptotic Cell Death and Their Role in Gliomas-Presentation of the Current State of Knowledge.

Nafe R, Hattingen E Biomedicines. 2024; 12(7).

PMID: 39062119 PMC: 11274595. DOI: 10.3390/biomedicines12071546.

Genome-wide DNA methylation profiling of HPV-negative leukoplakia and gingivobuccal complex cancers.

Inchanalkar M, Srivatsa S, Ambatipudi S, Bhosale P, Patil A, Schaffer A Clin Epigenetics. 2023; 15(1):93.

PMID: 37245006 PMC: 10225107. DOI: 10.1186/s13148-023-01510-z.

References

Vigano E, Diamond C, Spreafico R, Balachander A, Sobota R, Mortellaro A . Human caspase-4 and caspase-5 regulate the one-step non-canonical inflammasome activation in monocytes. Nat Commun. 2015; 6:8761. PMC: 4640152. DOI: 10.1038/ncomms9761. View

Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister S . Glioma. Nat Rev Dis Primers. 2016; 1:15017. DOI: 10.1038/nrdp.2015.17. View

Kayagaki N, Wong M, Stowe I, Ramani S, Gonzalez L, Akashi-Takamura S . Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science. 2013; 341(6151):1246-9. DOI: 10.1126/science.1240248. View

Tang Z, Kang B, Li C, Chen T, Zhang Z . GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019; 47(W1):W556-W560. PMC: 6602440. DOI: 10.1093/nar/gkz430. View

Quail D, Joyce J . The Microenvironmental Landscape of Brain Tumors. Cancer Cell. 2017; 31(3):326-341. PMC: 5424263. DOI: 10.1016/j.ccell.2017.02.009. View

Ceccarelli M, Barthel F, Malta T, Sabedot T, Salama S, Murray B . Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016; 164(3):550-63. PMC: 4754110. DOI: 10.1016/j.cell.2015.12.028. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Liu J, Lichtenberg T, Hoadley K, Poisson L, Lazar A, Cherniack A . An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 2018; 173(2):400-416.e11. PMC: 6066282. DOI: 10.1016/j.cell.2018.02.052. View

Hanzelmann S, Castelo R, Guinney J . GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14:7. PMC: 3618321. DOI: 10.1186/1471-2105-14-7. View

10.

Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View

11.

Kayagaki N, Warming S, Lamkanfi M, Vande Walle L, Louie S, Dong J . Non-canonical inflammasome activation targets caspase-11. Nature. 2011; 479(7371):117-21. DOI: 10.1038/nature10558. View

12.

Yeh W, Lu D, Liou H, Fu W . A forward loop between glioma and microglia: glioma-derived extracellular matrix-activated microglia secrete IL-18 to enhance the migration of glioma cells. J Cell Physiol. 2011; 227(2):558-68. DOI: 10.1002/jcp.22746. View

13.

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

14.

Jackson C, Choi J, Lim M . Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nat Immunol. 2019; 20(9):1100-1109. DOI: 10.1038/s41590-019-0433-y. View

15.

Zheng X, Huang Y, Li K, Luo R, Cai M, Yun J . Immunosuppressive Tumor Microenvironment and Immunotherapy of Epstein-Barr Virus-Associated Malignancies. Viruses. 2022; 14(5). PMC: 9146158. DOI: 10.3390/v14051017. View

16.

Cristescu R, Lee J, Nebozhyn M, Kim K, Ting J, Wong S . Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015; 21(5):449-56. DOI: 10.1038/nm.3850. View

17.

Hanisch U, Kettenmann H . Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007; 10(11):1387-94. DOI: 10.1038/nn1997. View

18.

Tan A, Ashley D, Lopez G, Malinzak M, Friedman H, Khasraw M . Management of glioblastoma: State of the art and future directions. CA Cancer J Clin. 2020; 70(4):299-312. DOI: 10.3322/caac.21613. View

19.

Xu S, Zhang H, Yang X, Qian Y, Xiao Q . Inhibition of cathepsin L alleviates the microglia-mediated neuroinflammatory responses through caspase-8 and NF-κB pathways. Neurobiol Aging. 2017; 62:159-167. DOI: 10.1016/j.neurobiolaging.2017.09.030. View

20.

Ghosh A, Chaudhuri S . Microglial action in glioma: a boon turns bane. Immunol Lett. 2010; 131(1):3-9. DOI: 10.1016/j.imlet.2010.03.003. View